Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne
Edgewise Therapeutics, Inc. has announced an expansion of their clinical development program of EDG-5506. EDG-5506, which comes in the form of a small pill, is an investigational product that aims to protect muscles, specifically fast-twitch…Learn More